

4.0.03 DOC Cmte minutes

Neonatal Infection Guideline Update- Committee Meeting

Date: 27/11/2019

Location: NICE offices Manchester

Minutes: Final

| Committee members present: | |
|-----------------------------------|-------------------------|
| Waqar Shah (WS) (Chair) | Present for notes 1 – 9 |
| Sumiah Al-Azeib (SA) | Present for notes 1 – 9 |
| Philip Banfield (PB) | Present for notes 1 – 9 |
| Melanie Carpenter (MC) | Present for notes 1 – 9 |
| Mark Davies (MD) | Present for notes 1 – 9 |
| Nicole Gannon (NG) | Present for notes 1 – 9 |
| Jim Gray (JG) | Present for notes 1 – 9 |
| Paul Heath (PH) | Present for notes 1 – 9 |
| Stephanie Jenkins (SJ) | Present for notes 1 – 9 |
| Jane Plumb (JP) | Present for notes 1 – 9 |
| Aung Soe | Present for notes 1 – 9 |
| Richard Tubman (RT) | Present for notes 1 – 9 |

| In attendance: | | |
|----------------------------|--------------------------------------|-------------------------|
| Stacey Chang-Douglass (SC) | Technical Analyst – Health Economics | Present for notes 1 – 4 |
| Clare Dadswell (CD) | Technical Analyst | Present for notes 1 – 9 |
| Kathryn Hopkins (KH) | Technical Adviser | Present for notes 1 – 9 |
| Justine Karpusheff (JK) | Guidelines Commissioning | Present for notes 4 – 7 |

4.0.03 DOC Cmte minutes

| | | |
|---------------------|---|-------------------------|
| | Manager | |
| Vonda Murray (VM) | NICE - Project Manager | Present for notes 1 – 9 |
| Gabriel Rogers (GR) | NICE - Technical Adviser Health Economics | Present for notes 1 – 9 |

Apologies:

| | |
|--------------|--|
| Sue Spiers | NICE- Associate Director |
| Adam Storrow | NICE - Business Analyst - Resource Impact Assessment |

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 4th meeting on neonatal infections.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included:

- Health economic modelling
- Clinical evidence reviews for;
 - What maternal risk factors for late-onset neonatal infection should be used to guide management?
 - Which risk factors in the baby (including symptoms and signs) should raise suspicion of late-onset infection?
 - Which risk factors in the baby (including symptoms and signs) should raise suspicion of late-onset infection?
- Seek committee's views on managing overlap with NICE guideline on meningitis (bacterial) and meningococcal septicaemia in under 16s:

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting, no new interests were declared.

The DOI register was made available to the Chair and committee. The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.

4.0.03 DOC Cmte minutes

| |
|--|
| <p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p> |
| 2. Resource Impact introduction |
| <p>The introduction to resource impact, will be provided at the next committee meeting.</p> |
| 3. Health Economic modelling |
| <p>RQ7.1 What is the optimal antibiotic treatment regimen for suspected late-onset neonatal infection?</p> |
| <p>RQ7.2 What is the clinical and cost effectiveness of starting prophylactic antifungal treatment when starting antibiotic treatment for suspected late-onset neonatal infection?</p> |
| <p>The Chair introduced SC, Technical Analyst (Health Economics) who provided an update on the health economic models. The Chair thanked SC for their presentation.</p> |
| <p>4. RQ5.1 What maternal risk factors for late-onset neonatal infection should be used to guide management?</p> <ul style="list-style-type: none">• Presentation of clinical evidence |
| <p>The Chair introduced CD, Technical Analyst who gave a presentation on the maternal risk factors for late-onset neonatal infection. The Chair thanked CD for their presentation.</p> |
| <p>5. RQ5.2 Which risk factors in the baby (including symptoms and signs) should raise suspicion of late-onset infection?</p> <ul style="list-style-type: none">• Presentation of clinical evidence• Draft recommendations |
| <p>CD, Technical Analyst, gave a presentation on which risk factors in the baby (including symptoms and signs) should raise suspicion of late-onset infection.</p> |
| <p>6. Update of NICE guideline on meningitis (bacterial) and meningococcal septicaemia in under 16s: recognition, diagnosis and management (CG 102)'</p> |
| <p>The Chair introduced KH, Technical Adviser who facilitated a discussion with the committee on the updating of meningitis (bacterial) and meningococcal septicaemia in under 16s.</p> |
| <p>7. RQ6.1 What investigations should be performed before starting treatment in babies with symptoms of late-onset neonatal infection?</p> <ul style="list-style-type: none">• Clinical presentation |
| <p>The Chair introduced JG, Consultant Microbiologist who gave a presentation on the</p> |

4.0.03 DOC Cmte minutes

laboratory investigation of babies with symptoms or signs of late-onset infection. The Chair thanked JG for their presentation.

8. RQ6.1 What investigations should be performed before starting treatment in babies with symptoms of late-onset neonatal infection?

- **Presentation of clinical evidence**

CD, Technical Analyst gave a presentation on What investigations should be performed before starting treatment in babies with symptoms of late-onset neonatal infection The Chair thanked CD for their presentation.

9. AOB, summary and next steps

No other business to discuss

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

Date of next meeting: 16/01/2020 & 17/01/2020

Location of next meeting: NICE offices – Manchester